ERBB2 and gastric cancer: Furthermore, a phase II/III trial (NCT05980481) evaluating the safety and efficacy of RC48 in combination with toripalimab and chemotherapy or RC48 in combination with toripalimab and Herceptin as first-line treatment for patients with locally advanced or metastatic HER2-expressing GC and a phase III trial (NCT04714190) evaluating the efficacy and safety of RC48 for the treatment of HER2-overexpressing locally advanced or metastatic GC are ongoing.